Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

A PROSPECTIVE STUDY OF THE TREATMENT OF 100 PERIPROSTHETIC INFECTIONS AFTER TOTAL HIP ARTHROPLASTY



Abstract

Introduction: The goal of the study was to evaluate our treatment protocols for peri-prosthetic infection after total hip replacement.

Méthode: A prospective study carried out between February 2003 and February 2005, included 100 patients treated for peri-prosthetic infection after total hip replacement. Debridement and prosthesis retention was performed in case of duration of symptoms of less than 14 days (11 cases), otherwise a one-stage (42 cases) or a two-stages (41 cases) prosthesis removal and re-implantation were carried out. A two-stage procedure was decided in case of important bone loss or undetermined germ. If general health state did not allow a re-implantation, an isolated prosthesis removal was performed (6 cases). Post-operatively, patients received intravenous antibiotics (6 weeks), then oral antibiotics (6 weeks). The mean follow-up was 2.2 years with no lost to follow-up. The main evaluation criteria was the rate of infection eradication with 2 years minimal follow -up. In case of a suspected new infection, a hip aspiration was performed to determine whether it was a non-eradication (same germ) or a new re-infection (other germ) which was not considered as a failure.

Results: Infection eradication rate was 95% and 100% for the one-stage surgical procedure. 5 failures were recorded (2 deaths and 3 non-eradications). However, 3 patients were re-infected with different germs. The rate of non-infected patiens at the last follow-up was 92%.

Conclusion: Our protocols were validated with a high success rate of 95%. Peri-prosthetic infection of the hip is severe even if well treated with a mortality rate of 2%.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org